Clinical Trials
Personalized mRNA Vaccine Shows Promise in Extending Pancreatic Cancer Survival
A personalized mRNA vaccine has demonstrated potential to meaningfully extend survival for pancreatic cancer patients, according to six-year trial results presented at a major oncology conference.
Soligenix Reports Positive Interim and Comparative Data for CTCL Treatment HyBryte
Soligenix announced consistent interim response rates from its phase 3 FLASH2 study and positive comparative results for HyBryte against Valchlor in cutaneous T-cell lymphoma, highlighting progress for a disease with limited treatment options.
Combination Strategies Reshape Precision Oncology as Lixte Advances First-in-Class PP2A Inhibitor
Lixte Biotechnology's LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy, exemplifies the industry shift toward combination regimens to overcome resistance in solid tumors.
LIXTE Biotechnology Advances LB-100 as a Novel Cancer Treatment Enhancer
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, aims to boost the effectiveness of existing chemotherapies and immunotherapies in hard-to-treat cancers, with ongoing clinical trials for ovarian, colon, and soft tissue sarcomas.
Soligenix Reports Encouraging Interim Data and Positive Comparative Results for CTCL Therapy
Soligenix released promising interim analysis from its phase 3 FLASH2 study and positive comparative results for HyBryte versus Valchlor, reinforcing its progress in developing treatments for cutaneous T-cell lymphoma.
Ocumetics Reports Life-Changing Six-Month Results from First-in-Human Study of Accommodating Intraocular Lens
Ocumetics Technology Corp. announced that six-month postoperative results from its first-in-human study of the Ocumetics Accommodating Intraocular Lens show continued vision improvements and meaningful quality-of-life enhancements for patients, with plans to advance to Group Two surgeries.
Lantern Pharma Seeks FDA Feedback on HARMONIC Trial Protocol Amendments for Lung Cancer Drug
Lantern Pharma has scheduled a Type C meeting with the FDA to discuss proposed changes to its Phase 2 HARMONIC trial for LP-300 in non-small cell lung cancer, focusing on EGFR Exon 21 L858R patients based on promising clinical data.
Oragenics Reports Early Progress in Phase IIa Trial of Intranasal Concussion Therapy
Oragenics Inc. has enrolled two patients and administered eight doses in its Phase IIa trial for ONP-002, a potential first-in-class intranasal treatment for mild traumatic brain injury, addressing a significant unmet medical need in a market with no FDA-approved pharmacological therapies.
Soligenix Gains European Orphan Drug Designation for Behçet's Disease Therapy SGX945
The European Commission granted orphan drug designation to Soligenix's SGX945 for treating Behçet's disease, validating the therapy's potential and providing regulatory and commercial incentives for development in a rare disease area with significant unmet need.
LIXTE Biotechnology's LB-100 Represents Novel Cancer Treatment Approach Through PP2A Inhibition
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor designed to enhance existing cancer therapies by making tumors more responsive to chemotherapy and immunotherapy in multiple clinical programs targeting solid tumors with significant unmet medical need.
New Oral Rinse Demonstrates Superior Gingivitis Protection in Saliva Environment
ioRinse Ultra has shown complete elimination of gingivitis-causing bacteria within 30 seconds in saliva-inclusive testing, addressing a critical gap in traditional oral rinse evaluation that could transform daily oral care routines.
Soligenix CEO Advocates for Patient-Centric Drug Reformulation to Improve Treatment Access and Adherence
Soligenix CEO Christopher Schaber argues that reformulating therapies to better align with patients' daily lives can enhance treatment access, adherence, and clinical trial success, reflecting a broader industry shift toward patient-centered drug development.
Cybin Reports Strong Q2 2025 Results and Advances Late-Stage Neuropsychiatry Programs
Cybin Inc. has reported strong institutional demand in its second-quarter 2025 results while advancing multiple late-stage clinical programs for mental health treatments, positioning the company for key 2026 data readouts that could significantly impact neuropsychiatry treatment options.
Lantern Pharma Reports Strong Q3 2025 Results with AI-Driven Oncology Pipeline Advances
Lantern Pharma demonstrated significant clinical progress in its AI-driven oncology programs, including successful Phase 1a trial results for LP-184 and regulatory clarity for pediatric CNS cancer development, positioning the company to address multiple high-value cancer markets.
Oragenics Regains NYSE Compliance While Advancing Neurological Therapeutics Pipeline
Oragenics Inc. has regained full NYSE American compliance while making significant progress toward its first clinical trial and expanding its neurological therapeutics pipeline through an AI-driven collaboration with Receptor.AI.
Annovis Bio Advances Alzheimer's Treatment with Phase 3 Trial Progress and Promising Biomarker Data
Annovis Bio reports significant progress in its Phase 3 Alzheimer's trial with full site activation and promising biomarker data showing buntanetap's disease-modifying potential, positioning the company for potential regulatory submission.
Cybin to Present Neuropsychiatry Pipeline at Jefferies Global Healthcare Conference
Cybin Inc. will present its late-stage neuropsychiatry pipeline including breakthrough-designated depression treatment at the Jefferies Global Healthcare Conference, highlighting the company's progress in developing novel mental health therapies.
March Biosciences Receives FDA RMAT Designation for CAR-T Therapy Targeting Aggressive T-Cell Lymphoma
The FDA granted RMAT designation to March Biosciences' MB-105 CAR-T therapy for relapsed T-cell lymphoma, potentially accelerating treatment development for patients with limited survival options.
NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Development
NanoViricides has raised $6 million through a registered direct offering and concurrent private placement, providing crucial capital to advance its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
HOPE Therapeutics Launches Revolutionary One-Day Depression Treatment Protocol in Florida
NRx Pharmaceuticals' subsidiary HOPE Therapeutics has initiated Florida's first deployment of a rapid one-day TMS protocol for treatment-resistant depression, potentially transforming care for millions suffering from depression and PTSD.
NanoViricides Receives Regulatory Approval for Phase II MPox Trial in Democratic Republic of Congo
NanoViricides has received regulatory approval to begin Phase II clinical trials for its broad-spectrum antiviral drug NV-387 to treat MPox in the Democratic Republic of Congo, representing a potential breakthrough in antiviral therapy.
Polypill Strategy Shows Promise for Heart Failure Treatment, Improving Outcomes and Medication Adherence
A new study demonstrates that a once-daily combination pill for heart failure patients significantly improves heart function, reduces hospitalizations, and enhances quality of life compared to traditional multi-pill regimens.
PCSK9 Inhibitor Combined with Statin Shows Significant LDL Reduction in Heart Transplant Patients
A clinical trial demonstrates that adding the PCSK9 inhibitor alirocumab to statin therapy reduces LDL cholesterol by more than 50% in heart transplant patients, though it did not prevent the development of cardiac allograft vasculopathy.
Healthy Food Delivery Programs Improve Quality of Life for Heart Failure Patients, Study Finds
A new study shows that providing medically tailored meals or fresh produce alongside dietary counseling significantly improves quality of life for heart failure patients following hospitalization, highlighting the potential of food-based interventions in chronic disease management.
Study Finds Prasugrel May Offer Better Outcomes Than Ticagrelor for Diabetic Patients With Stents
New research presented at the American Heart Association's Scientific Sessions 2025 suggests prasugrel may be more effective than ticagrelor at preventing heart attacks, strokes, bleeding complications and death in diabetic patients who received coronary stents, challenging current interchangeable use of these antiplatelet medications.
Family-Based Program Reduces Blood Pressure by 10 mm Hg in Rural Chinese Communities
A family-focused health intervention in rural China achieved significant blood pressure reductions through community support and lifestyle changes, offering a scalable model for cardiovascular disease prevention in resource-limited areas.
Financial Incentives Double Blood Pressure Medication Use But Fail to Improve Health Outcomes
A new study reveals that while daily cash rewards doubled medication adherence among high blood pressure patients, the improved compliance did not translate to better blood pressure control, highlighting the complexity of long-term behavior change.
Food Delivery and Dietary Counseling Program Shows Promise in Reducing Blood Pressure for Black Adults in Food Deserts
A study presented at the American Heart Association's Scientific Sessions 2025 demonstrates that providing home-delivered groceries and dietary counseling significantly improved blood pressure and cholesterol levels in Black adults living in food deserts, though benefits disappeared when support ended, highlighting the need for sustained interventions to address food access barriers.
American Heart Association Launches National Initiative to Combat Rising Heart Valve Disease Deaths
The American Heart Association has launched a comprehensive Heart Valve Initiative to address the growing mortality from heart valve disease, which affects over 28 million people worldwide and contributes to more than 60,000 annual U.S. deaths through improved diagnosis, treatment protocols, and public awareness.
Tailored Vitamin D Doses Reduce Heart Attack Risk by 52% in Heart Disease Patients
Adults with heart disease who received personalized vitamin D supplementation to achieve optimal blood levels experienced more than half the risk of heart attack compared to those without vitamin D monitoring, according to preliminary research presented at the American Heart Association's Scientific Sessions 2025.